Immuneworks schedules Phase 2 trials for long-acting octreotide TE-8214
The company says early clinical signals were positive and plans studies in Taiwan and Australia in the fourth quarter of 2026.
The wire
- 01Immuneworks reported what it calls positive clinical signals for TE-8214, a long-acting octreotide formulation, and scheduled Phase 2 trials in Taiwan and Australia for Q4 2026.
- 02Long-acting somatostatin analogs are a core approved-peptide category, and a new depot entrant would compete in acromegaly and neuroendocrine tumour care.
- 03Details of the early data, dosing interval and endpoints were not disclosed in the announcement, which comes from the company rather than a peer-reviewed report.
From the source
Read at ibmi.taiwan-healthcare.orgImmuneworks Reports Positive Clinical Signals for Long-Acting Octreotide TE-8214, Schedules Phase 2 Trials in Taiwan and Australia for Q4 2026｜Institute for Biotechnology and Medicine Industry│IBMI
